GLP-1
The program connects self-pay patients with clinicians to access GLP-1s, including Wegovy, starting at $149 per month, with no subscription fee.
The pharma giant alleges that Hims & Hers is infringing its patents and misleading consumers by selling unsafe, unapproved compounded versions of its semaglutide drugs.
The collaboration will allow patients considering the oral GLP-1 therapy to access metabolic care through knownwell’s hybrid model.
Ash will provide at-home biomarker testing to Noom users to provide insights into key health markers linked to chronic disease risk and aging.
The company will scale its weight loss offerings ahead of generic GLP-1s coming to the Canadian market in 2026.
Ozempic and Wegovy pens will be available via GoodRx for $499 per month.
The Microdose GLP-1Rx Program will offer low-dose GLP-1 prescriptions combined with behavioral coaching, clinical monitoring and medication management.
The partnership has been terminated less than two months after launch as Novo Nordisk alleges Hims & Hers is illegally selling copycat drugs and using deceptive marketing practices.
Patients will get same-day delivery and access to treatments like GLP-1s and hormone therapies.
Personify’s Transform Weight Management program will provide LucyRx members with personalized, coach-led guidance, incentives and assets to help manage their weight and medication.